High-throughput screening of excipients intended to prevent antigen aggregation at air-liquid interface

Pharmaceutical Research

Volumn 28, Issue 7, 2011, Pages 1591-1605

  Dasnoy, Sébastien ^a   Dezutter, Nancy ^b   Lemoine, Dominique ^b   Le Bras, Vivien ^b   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

excipients; fluorescence spectroscopy; high throughput screening; protein aggregation; vaccines

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMINO ACID; ANTIGEN 18A; ARGININE; ASPARTIC ACID; CYCLODEXTRIN; DOCUSATE SODIUM; EXCIPIENT; GAMMA CYCLODEXTRIN; GLYCINE; HISTIDINE; ISOLEUCINE; LEUCINE; MACROGOL STEARATE; MANNITOL; POLOXAMER; POLYMER; POLYOL; POLYSORBATE 80; POVIDONE; PROLINE; RECOMBINANT ANTIGEN; SERINE; SORBITOL; SUCROSE; SUGAR; SURFACTANT; THREONINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VALINE;

AIR; ARTICLE; CONTROLLED STUDY; FLUORESCENCE SPECTROSCOPY; GEL PERMEATION CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; INFRARED SPECTROSCOPY; LIQUID; MECHANICAL STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; TURBIDIMETRY;

AIR; ANIMALS; ANTIGENS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCIPIENTS; GLYCOPROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS; PROTEIN STABILITY; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; WATER;

EID: 79959868514     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0393-x     Document Type: Article

References (44)

1. N Rathore RS Rajan 2008 Current perspectives on stability of protein drug products during formulation, fill and finish operations Biotechnol Prog. 24 3 504 514 18484778 10.1021/bp070462h 1:CAS:528:DC%2BD1cXlvFaktrc%3D (Pubitemid 351832704)
2. W Wang 2005 Protein aggregation and its inhibition in biopharmaceutics Int J Pharm. 289 1-2 1 30 15652195 10.1016/j.ijpharm.2004.11.014 1:CAS:528:DC%2BD2MXisFKjsg%3D%3D (Pubitemid 40093537)
3. S Hermeling DJ Crommelin H Schellekens W Jiskoot 2004 Structure-immunogenicity relationships of therapeutic proteins Pharm Res. 21 6 897 903 15212151 10.1023/B:PHAM.0000029275.41323.a6 1:CAS:528: DC%2BD2cXktlykurY%3D (Pubitemid 38870136)
4. V Hlady J Buijs HP Jennissen 1999 Methods for studying protein adsorption Methods Enzymol. 309 402 429 10507038 10.1016/S0076-6879(99)09028-X 1:CAS:528:DC%2BD3cXksVKgtQ%3D%3D (Pubitemid 29446463)
5. V Sluzky JA Tamada AM Klibanov R Langer 1991 Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces PNAS 88 21 9377 9381 1946348 10.1073/pnas.88.21.9377 1:CAS:528:DyaK3MXmslSrtrg%3D (Pubitemid 21915634)
6. M Katakam AK Banga 1995 Aggregation of insulin and its prevention by carbohydrate excipients PDA J Pharm Sci Technol. 49 4 160 165 7552234 1:CAS:528:DyaK2MXotFems70%3D
7. J Bringer A Heldt GM Grodsky 1981 Prevention of insulin aggregation by dicarboxylic amino acids during prolonged infusion Diabetes. 30 1 83 85 6112178 10.2337/diabetes.30.1.83 1:CAS:528:DyaL3MXhs1altb0%3D (Pubitemid 11022629)
8. S Soenderkaer M van de Weert LL Hansen J Flink S Frokjaer 2005 Evaluation of statistical design/modeling for prediction of the effect of amino acids on agitation-induced aggregation of human growth hormone and human insulin Drug Del Sci Tech. 15 427 434 1:CAS:528:DC%2BD28XktVyhsw%3D%3D (Pubitemid 41695890)
9. R Quinn JD Andrade 1983 Minimizing the aggregation of neutral insulin solutions J Pharm Sci. 72 12 1472 1473 6363674 10.1002/jps.2600721227 1:CAS:528:DyaL2cXls1Orug%3D%3D (Pubitemid 14208330)
10. SA Charman KL Mason WN Charman 1993 Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone Pharm Res. 10 7 954 962 8378257 10.1023/A:1018994102218 1:CAS:528:DyaK3sXlvVyntr8%3D (Pubitemid 23211415)
11. YF Maa CC Hsu 1997 Protein denaturation by combined effect of shear and air-liquid interface Biotechnol Bioeng. 54 6 503 512 18636406 10.1002/(SICI)1097-0290(19970620)54:6<503::AID-BIT1>3.0.CO;2-N 1:CAS:528:DyaK2sXjtVWqtbg%3D (Pubitemid 27209319)
12. M Katakam AK Banga 1997 Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses Pharm Dev Technol. 2 2 143 149 9552440 10.3109/10837459709022619 1:CAS:528: DyaK2sXjvVygsbo%3D (Pubitemid 28252530)
13. M Katakam LN Bell AK Banga 1995 Effect of surfactants on the physical stability of recombinant human growth hormone J Pharm Sci. 84 6 713 716 7562409 10.1002/jps.2600840609 1:CAS:528:DyaK2MXlslyrsr4%3D
14. NB Bam JL Cleland J Yang MC Manning JF Carpenter RF Kelley, et al. 1998 Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions J Pharm Sci. 87 12 1554 1559 10189266 10.1021/js980175v 1:CAS:528:DyaK1cXntVWlsbo%3D (Pubitemid 28559641)
15. M Hagenlocher R Pearlman 1989 Use of a substituted cyclodextrin for stabilization of solutions of recombinant human growth hormone Pharm Res. 6 S30
16. DK Chou R Krishnamurthy TW Randolph JF Carpenter MC Manning 2005 Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation J Pharm Sci. 94 6 1368 1381 15858848 10.1002/jps.20365 1:CAS:528:DC%2BD2MXkvF2qtbo%3D (Pubitemid 40904199)
17. HC Mahler R Muller W Friess A Delille S Matheus 2005 Induction and analysis of aggregates in a liquid IgG1-antibody formulation Eur J Pharm Biopharm. 59 3 407 417 15760721 10.1016/j.ejpb.2004.12.004 1:CAS:528: DC%2BD2MXit1Chsr8%3D (Pubitemid 40342515)
18. S Kiese A Pappenberger W Friess HC Mahler 2008 Shaken, not stirred: mechanical stress testing of an IgG1 antibody J Pharm Sci. 97 10 4347 4366 18240293 10.1002/jps.21328 1:CAS:528:DC%2BD1cXht1Sgt7vF
19. T Serno JF Carpenter TW Randolph G Winter 2010 Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta- cyclodextrin J Pharm Sci. 99 3 1193 1206 19774651 1:CAS:528: DC%2BC3cXmvVGgtg%3D%3D
20. R Thirumangalathu S Krishnan MS Ricci DN Brems TW Randolph JF Carpenter 2009 Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution J Pharm Sci. 98 9 3167 3181 19360857 10.1002/jps.21719 1:CAS:528:DC%2BD1MXptl2itrc%3D
21. O Joshi L Chu J McGuire DQ Wang 2009 Adsorption and function of recombinant Factor VIII at the air-water interface in the presence of Tween 80 J Pharm Sci. 98 9 3099 3107 18781611 10.1002/jps.21569 1:CAS:528: DC%2BD1MXptl2isbs%3D
22. L Kreilgaard LS Jones TW Randolph S Frokjaer JM Flink MC Manning, et al. 1998 Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII J Pharm Sci. 87 12 1597 1603 10189273 1:CAS:528:DyaK1cXmtlKgt78%3D (Pubitemid 28559648)
23. W Wang YJ Wang DQ Wang 2008 Dual effects of Tween 80 on protein stability Int J Pharm. 347 1-2 31 38 17692480 10.1016/j.ijpharm.2007.06.042 1:CAS:528:DC%2BD2sXhtlOjsrnI (Pubitemid 350180316)
24. AK Banga R Mitra 1993 Minimization of shaking-induced formation of insoluble aggregates of insulin by cyclodextrins J Drug Target. 1 4 341 345 8069577 10.3109/10611869308996093 1:CAS:528:DyaK2cXjtVOhtLc%3D
25. H Zhao O Graf N Milovic X Luan M Bluemel M Smolny, et al. 2010 Formulation development of antibodies using robotic system and High-Throughput Laboratory (HTL) J Pharm Sci. 99 5 2279 2294 20014026 1:CAS:528: DC%2BC3cXjt1agt7o%3D
26. MA Capelle R Gurny T Arvinte 2009 A high throughput protein formulation platform: case study of salmon calcitonin Pharm Res. 26 1 118 128 18600433 10.1007/s11095-008-9662-8 1:CAS:528:DC%2BD1cXhsFSjsrzO
27. SF Ausar J Chan W Hoque O James K Jayasundara K Harper 2011 Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines J Pharm Sci. 100 2 431 440 20740682 10.1002/jps.22282 1:CAS:528:DC%2BC3cXhs1ags7fP
28. J Kyte RF Doolittle 1982 A simple method for displaying the hydropathic character of a protein J Mol Biol. 157 1 105 132 7108955 10.1016/0022-2836(82) 90515-0 1:CAS:528:DyaL38Xks1yjtro%3D
29. Lakowicz JR. Principles of fluorescence spectroscopy. New York: Springer; 2004.
30. EL McGown DG Hafeman 1998 Multichannel pipettor performance verified by measuring pathlength of reagent dispensed into a microplate Anal Biochem. 258 1 155 157 9527867 10.1006/abio.1998.2621 1:CAS:528:DyaK1cXitlKhsLs%3D (Pubitemid 28163162)
31. E Goormaghtigh JM Ruysschaert V Raussens 2006 Evaluation of the information content in infrared spectra for protein secondary structure determination Biophys J. 90 8 2946 2957 16428280 10.1529/biophysj.105.072017 1:CAS:528:DC%2BD28XjsFequrg%3D
32. BS Kendrick A Dong SD Allison MC Manning JF Carpenter 1996 Quantitation of the area of overlap between second-derivative amide I infrared spectra to determine the structural similarity of a protein in different states J Pharm Sci. 85 2 155 158 8683440 10.1021/js950332f 1:CAS:528:DyaK28XjtFyisg%3D%3D (Pubitemid 26055795)
33. Oehlert GW. A first course in design and analysis of experiments. New York: W.H. Freeman & Co; 2000.
34. JH Zhang TD Chung KR Oldenburg 1999 A simple statistical parameter for use in evaluation and validation of high throughput screening assays J Biomol Screen. 4 2 67 73 10838414 10.1177/108705719900400206 (Pubitemid 29278954)
35. DL Sackett J Wolff 1987 Nile red as a polarity-sensitive fluorescent probe of hydrophobic protein surfaces Anal Biochem. 167 2 228 234 3442318 10.1016/0003-2697(87)90157-6 1:CAS:528:DyaL1cXhvVKqtw%3D%3D
36. M Sutter S Oliveira NN Sanders B Lucas A van Hoek MA Hink, et al. 2007 Sensitive spectroscopic detection of large and denatured protein aggregates in solution by use of the fluorescent dye Nile red J Fluoresc. 17 2 181 192 17294134 10.1007/s10895-007-0156-6 1:CAS:528:DC%2BD2sXisV2htbo%3D (Pubitemid 46355026)
37. DM Byler H Susi 1986 Examination of the secondary structure of proteins by deconvolved FTIR spectra Biopolymers. 25 3 469 487 3697478 10.1002/bip.360250307 1:CAS:528:DyaL28Xht1GqtLc%3D
38. A Dong P Huang WS Caughey 1990 Protein secondary structures in water from second-derivative amide I infrared spectra Biochemistry. 29 13 3303 3308 2159334 10.1021/bi00465a022 1:CAS:528:DyaK3cXhsFCltrg%3D (Pubitemid 20131472)
39. Pain RH. Determining the fluorescence spectrum of a protein. Curr Protoc Protein Sci. 2004;S38:7.7.1-7.7.20.
40. JF Carpenter TW Randolph W Jiskoot DJ Crommelin CR Middaugh G Winter 2010 Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products J Pharm Sci. 99 5 2200 2208 19918982 10.1002/jps.21989 1:CAS:528:DC%2BC3cXjt1ahurg%3D
41. L Jorgensen S Hostrup EH Moeller H Grohganz 2009 Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients Expert Opin Drug Deliv. 6 11 1219 1230 19678792 10.1517/17425240903199143 1:CAS:528:DC%2BD1MXhtlWlsLfJ
42. HS Samra F He A Bhambhani JD Pipkin R Zimmerer SB Joshi, et al. 2010 The effects of substituted cyclodextrins on the colloidal and conformational stability of selected proteins J Pharm Sci. 99 6 2800 2818 20049940 1:CAS:528:DC%2BC3cXkvVOkurg%3D
43. W Saski SG Shah 1965 Availability of drugs in the presence of surface-active agents. I. Critical micelle concentrations of some oxyethylene oxypropylene polymers J Pharm Sci. 54 71 74 14288499 10.1002/jps.2600540117 1:CAS:528:DyaF2MXltVOrsw%3D%3D
44. J Rassing D Attwood 1982 Ultrasonic velocity and light-scattering studies on the polyoxyethylene-polyoxypropylene copolymer Pluronic F127 in aqueous solution Int J Pharm. 13 1 47 55 10.1016/0378-5173(82)90141-7 1:CAS:528:DyaL3sXnvVSnuw%3D%3D (Pubitemid 13221124)